What happened with ACB today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Aurora Cannabis grows cannabis and processes it into products for medical patients. Medical cannabis provides most of its revenue, with international sales contributing more than Canadian medical sales. Dried flower is its largest product category, followed by extracts. Its Canadian recreational cannabis business now has very limited activity and is being wound down.
In Canada, registered patients buy directly through Aurora’s online shop or client care centre, rather than through provincial wholesalers or private retailers. Abroad, Aurora supplies medical cannabis to wholesale buyers and pharmacies; in Germany, it sells both directly to pharmacies and through wholesalers. Canada, Germany, the United Kingdom, Poland and Australia are its principal medical markets.
The business depends on permission to grow, distribute and export cannabis. Canadian licences are tied to individual facilities, while overseas sales require local approvals and compliance with each market’s rules. Certifications confirming pharmaceutical manufacturing standards at certain Canadian and German facilities allow Aurora to supply tightly regulated markets. Canadian medical earnings also depend on federal reimbursement terms, which have changed to provide less reimbursement.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Canopy Growth Corporation competes with Aurora for medical cannabis patients and distribution outlets in Canada, Germany, Poland and Australia. Watch its German medical sales, where Aurora supplies pharmacies in a market offering higher dried-flower prices than Canada.
Tilray Brands, Inc. competes with Aurora to supply medical cannabis in Canada and Europe, including to German pharmacies. Its medical cannabis business is the relevant comparison, rather than its substantial non-cannabis businesses.
IM Cannabis Corp. and Aurora compete to supply German pharmacies, so German patient demand and competition from imports matter to both. Watch IM Cannabis's German sales through Adjupharm, which imports cannabis from supply partners and delivers it to licensed pharmacies.
Aurora is due to buy premium cannabis flower from Sundial Growers Inc. (SNDL) under a three-year agreement worth an estimated CAD 27 million. SNDL also sells cannabis into medical and export markets, so watch its flower deliveries to Aurora as well as its sales into markets where the two compete.
Cronos Group Inc. Common Share competes with Aurora for Canadian medical cannabis patients, but sells through third-party distributors while Aurora sells directly to registered patients. Its Canadian medical sales are the closer comparison for Aurora than its substantial adult-use business.
Village Farms International, Inc. and Aurora both produce cannabis in Canada and compete to supply international medical cannabis markets. Its Canadian cannabis business, including Pure Sunfarms and Rose LifeScience, is the relevant operation to watch rather than its fresh-produce or renewable-gas businesses.
Organigram Global Inc. competes with Aurora in supplying Canadian medical cannabis patients and exporting flower to international medical markets. Its medical flower exports are the closer comparison for Aurora, despite Organigram's greater emphasis on adult-use cannabis.
Intercure Ltd. explicitly names Aurora as a competitor in selling pharmaceutical-grade medical cannabis, with some distribution exposure to Europe. Watch its German pharmaceutical distribution agreement for developments in access to that market; some of its other European collaborations have been terminated.
Sundial Growers Inc. earningsSNDL
SNDL's report can offer clues about the flower supply Aurora is due to buy and show how SNDL is selling in medical and export markets they share.
Look for SNDL's flower output or any disclosed deliveries, alongside its medical and export sales; SNDL may not name Aurora in its report. Steady output or continuing disclosed deliveries would support the view that supply is flowing, but would not prove Aurora received the product. Weaker output or deliveries would put that source in question. Separately, growing medical and export sales would show SNDL winning sales in markets they share; weaker sales would soften that competitive signal, but would not by themselves establish market demand.
Aurora Cannabis Inc. earningsThis company
Aurora's report will show whether growth in international medical cannabis is offsetting lower reimbursement for its Canadian direct-to-patient business.
Read Canadian and international medical cannabis net revenue together, then check gross margin before fair-value adjustments—the profit percentage before required non-cash revaluations. Growing international revenue with a steady margin would show overseas sales are absorbing the Canadian reimbursement hit. If international growth falls short or the margin drops, the reimbursement change and lower-margin sales mix are outweighing growth, leaving Aurora's medical business under pressure.
Cronos Group Inc. earningsCRON
Cronos Group's report will show how its third-party distribution channel is selling Canadian medical cannabis, giving Aurora a comparison for its direct-to-patient business.
Compare the direction of Cronos's Canadian medical sales with Aurora's Canadian medical revenue, but not as like-for-like figures: Cronos sells through third-party distributors, while Aurora sells directly to registered patients. Cronos growth would show a rival channel gaining sales; a decline would weaken the evidence of competitive pressure, but would not prove patient demand is falling. Read the result as a signal about a competing channel, not as a verdict on the whole market.
Canopy Growth Corporation earningsCGC
Canopy Growth's report will show how its German medical cannabis sales are faring in a market where Aurora also supplies pharmacies and competes for patient demand.
Look at Canopy's German medical sales alongside Aurora's disclosed European or international medical revenue. Canopy growth would show that German pharmacies are generating sales, but also that a competitor is capturing revenue there; that figure alone cannot separate market growth from sales shifting between suppliers. A decline would weaken the signal of intensifying competition, but would not establish that demand or prices are falling. Aurora's own European medical revenue shows whether it is also benefiting from that demand.
